Inadvertent intrathecal administration of vincristine [6]

Journal of Pharmacy Practice and Research

Volumn 34, Issue 2, 2004, Pages 159-

  Gilbar, Peter ^a   Carrington, Christine ^a  

^a Soc of Hosp Pharmacists Australia   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; VINCRISTINE;

CANCER CHEMOTHERAPY; CASE REPORT; CAUSE OF DEATH; DRUG LABELING; HUMAN; LETTER; MALE; MEDICATION ERROR; MORTALITY; NEUROTOXICITY; ONCOLOGY; PARALYSIS; PRACTICE GUIDELINE;

EID: 3543031037     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Schochet SS Jr, Lampert PW, Earle KM. Neuronal changes induced by intrathecal vincristine sulfate. J Neuropathol Exp Neurol 1968; 27: 645-58.
2. Davis J. Intrathecal drug administration [letter]. Aust J Hosp Pharm 1995; 25: 174.
3. Stefanou A, Dooley M. Simple method to eliminate the risk of inadvertent intrathecal vincristine administration [letter]. J Clin Oncol 2003; 21: 2044.
4. Meggs WJ, Hoffman RS. Fatality resulting from intraventricular vincristine administration. J Toxicol Clin Toxicol 1998; 36: 243-6.
5. Woods K. The prevention of intrathecal medication errors. A report to the Chief Medical Officer. Department of Health, London; 2001. Available from 〈www.doh.gov.uk/imeprevent/index.htm〉